CAMP4 THERAPEUTICS Ownership

CAMP Stock  USD 1.55  0.04  2.52%   
CAMP4 THERAPEUTICS holds a total of 20.16 Million outstanding shares. Over half of CAMP4 THERAPEUTICS's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
1985-06-30
Previous Quarter
19.5 M
Current Value
20.2 M
Avarage Shares Outstanding
19.9 M
Quarterly Volatility
10.6 M
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of 08/26/2025, Dividend Paid And Capex Coverage Ratio is likely to grow to -98.15. As of 08/26/2025, Common Stock Shares Outstanding is likely to grow to about 23.3 M.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CAMP4 THERAPEUTICS PORATION. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

CAMP4 Stock Ownership Analysis

About 35.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.08. CAMP4 THERAPEUTICS recorded a loss per share of 2.64. The entity had not issued any dividends in recent years. The firm had 1:23 split on the 2nd of February 2024. CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company was incorporated in 1981 and is headquartered in Irvine, California. CalAmp Corp operates under Communication Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 887 people. For more info on CAMP4 THERAPEUTICS PORATION please contact Joshua MandelBrehm at 617-651-8867 or go to https://www.camp4tx.com.
Besides selling stocks to institutional investors, CAMP4 THERAPEUTICS also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CAMP4 THERAPEUTICS's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CAMP4 THERAPEUTICS's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

CAMP4 THERAPEUTICS Quarterly Liabilities And Stockholders Equity

51.27 Million

About 35.0% of CAMP4 THERAPEUTICS PORATION are currently held by insiders. Unlike CAMP4 THERAPEUTICS's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CAMP4 THERAPEUTICS's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of CAMP4 THERAPEUTICS's insider trades

CAMP4 THERAPEUTICS Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CAMP4 THERAPEUTICS insiders, such as employees or executives, is commonly permitted as long as it does not rely on CAMP4 THERAPEUTICS's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CAMP4 THERAPEUTICS insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Ragan Paula over two months ago
Acquisition by Ragan Paula of 9000 shares of CAMP4 THERAPEUTICS at 1.56 subject to Rule 16b-3
 
Mandel-brehm Josh over two months ago
Acquisition by Mandel-brehm Josh of 160000 shares of CAMP4 THERAPEUTICS at 3.86 subject to Rule 16b-3
 
Mandel-brehm Josh over three months ago
Acquisition by Mandel-brehm Josh of 160000 shares of CAMP4 THERAPEUTICS at 3.86 subject to Rule 16b-3
 
Jikun Kim over six months ago
Acquisition by Jikun Kim of 200004 shares of CAMP4 THERAPEUTICS subject to Rule 16b-3
 
Nathan Lowstuter over six months ago
Disposition of 625 shares by Nathan Lowstuter of CAMP4 THERAPEUTICS at 4.53 subject to Rule 16b-3
 
Nathan Lowstuter over six months ago
Disposition of 1534 shares by Nathan Lowstuter of CAMP4 THERAPEUTICS subject to Rule 16b-3
 
Richard Scott over six months ago
Disposition of 3167 shares by Richard Scott of CAMP4 THERAPEUTICS subject to Rule 16b-3
 
Clark Jeffrey P. over six months ago
Disposition of 1448 shares by Clark Jeffrey P. of CAMP4 THERAPEUTICS subject to Rule 16b-3
 
Nathan Lowstuter over six months ago
Disposition of 10000 shares by Nathan Lowstuter of CAMP4 THERAPEUTICS subject to Rule 16b-3
 
Nathan Lowstuter over a year ago
Disposition of 15 shares by Nathan Lowstuter of CalAmp Corp at 0.8766 subject to Rule 16b-3
 
Jikun Kim over a year ago
Disposition of 487 shares by Jikun Kim of CalAmp Corp at 3.68 subject to Rule 16b-3
 
Cummins Wes over a year ago
Acquisition by Cummins Wes of 25000 shares of CalAmp Corp at 3.9516 subject to Rule 16b-3

CAMP4 THERAPEUTICS Outstanding Bonds

CAMP4 THERAPEUTICS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CAMP4 THERAPEUTICS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CAMP4 bonds can be classified according to their maturity, which is the date when CAMP4 THERAPEUTICS PORATION has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with CAMP4 THERAPEUTICS

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CAMP4 THERAPEUTICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CAMP4 THERAPEUTICS will appreciate offsetting losses from the drop in the long position's value.

Moving together with CAMP4 Stock

  0.69ERNA Eterna TherapeuticsPairCorr

Moving against CAMP4 Stock

  0.56PFE Pfizer IncPairCorr
  0.49MRK Merck CompanyPairCorr
  0.44XENE Xenon PharmaceuticalsPairCorr
  0.33HCM HUTCHMED DRCPairCorr
The ability to find closely correlated positions to CAMP4 THERAPEUTICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CAMP4 THERAPEUTICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CAMP4 THERAPEUTICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CAMP4 THERAPEUTICS PORATION to buy it.
The correlation of CAMP4 THERAPEUTICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CAMP4 THERAPEUTICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CAMP4 THERAPEUTICS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CAMP4 THERAPEUTICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for CAMP4 Stock Analysis

When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.